| MOGAMULIZUMAB |
Poteligeo |
Kyowa Kirin Australia Pty Ltd |
Cutaneous T-cell lymphoma |
Sep 2025 |
Advice Provided |
| OSIMERTINIB |
Tagrisso® |
ASTRAZENECA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Sep 2025 |
Recommended |
| DAPAGLIFLOZIN |
Forxiga |
ASTRAZENECA PTY LTD |
Chronic kidney disease (CKD) |
Sep 2025 |
Recommended |
| NIVOLUMAB + IPILIMUMAB |
|
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Unresectable advanced and metastatic cancer |
Sep 2025 |
Recommended |
| ZOLBETUXIMAB |
Vyloy® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Gastric or gastroesophageal junction (G/GOJ) cancer |
Sep 2025 |
Recommended |
| VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTOR |
Alyftrek® |
VERTEX PHARMACEUTICALS PTY LTD |
Cystic fibrosis |
Sep 2025 |
Recommended |